G. Praxen Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-12-2024
- Paid Up Capital ₹ 0.10 M
as on 27-12-2024
- Company Age 6 Year, 20 Days
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2020)
- Profit -53.04%
(FY 2020)
- Ebitda -71.81%
(FY 2020)
- Net Worth -23.97%
(FY 2020)
- Total Assets 1167.63%
(FY 2020)
About G. Praxen Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sumeet Saxena, Siddhant Saxena, Vineet Saxena, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239UP2018PTC111745
- Company No.
111745
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at G. Praxen Pharmaceutical?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumeet Saxena  | Director | 28-Dec-2018 | Current |
| Siddhant Saxena | Director | 13-Feb-2024 | Current |
| Vineet Saxena | Director | 28-Dec-2018 | Current |
| Viranjani Saxena | Director | 28-Dec-2018 | Current |
Financial Performance of G. Praxen Pharmaceutical.
G. Praxen Pharmaceutical Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 53.04% decrease in profit. The company's net worth observed a substantial decline by a decrease of 23.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of G. Praxen Pharmaceutical?
Unlock access to G. Praxen Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
G Praxen And Co Private LimitedActive 77 years 8 monthsSumeet Saxena, Siddhant Saxena and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at G. Praxen Pharmaceutical?
Unlock and access historical data on people associated with G. Praxen Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of G. Praxen Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped G. Praxen Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
